BSE Live
Jan 02, 16:01Prev. Close
179.75
Open Price
179.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 02, 15:55Prev. Close
179.87
Open Price
179.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
182.19 (205)
| Key Financial Ratios of Marksans Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.01 | 0.01 | 0.42 | 1.93 | 6.37 | |
| Diluted EPS (Rs.) | 0.01 | 0.01 | 0.42 | 1.93 | 6.37 | |
| Cash EPS (Rs.) | 0.28 | 0.29 | 0.68 | 4.20 | 8.78 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 4.41 | 3.96 | 3.56 | 31.46 | 29.48 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 4.41 | 3.96 | 3.56 | 31.46 | 29.48 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 5.38 | 5.43 | 6.59 | 63.88 | 79.12 | |
| PBDIT/Share (Rs.) | 0.69 | 0.74 | 1.09 | 7.90 | 13.83 | |
| PBIT/Share (Rs.) | 0.42 | 0.48 | 0.85 | 5.86 | 11.59 | |
| PBT/Share (Rs.) | 0.02 | 0.06 | 0.54 | 2.66 | 8.71 | |
| Net Profit/Share (Rs.) | 0.01 | 0.01 | 0.42 | 1.93 | 6.37 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 12.76 | 13.64 | 16.51 | 12.36 | 17.48 | |
| PBIT Margin (%) | 7.79 | 8.77 | 12.88 | 9.17 | 14.65 | |
| PBT Margin (%) | 0.31 | 1.10 | 8.14 | 4.16 | 11.01 | |
| Net Profit Margin (%) | 0.14 | 0.24 | 6.30 | 3.01 | 8.04 | |
| Return on Networth / Equity (%) | 0.17 | 0.33 | 11.66 | 6.12 | 21.60 | |
| Return on Capital Employed (%) | 0.06 | 0.11 | 3.75 | 1.68 | 5.59 | |
| Return on Assets (%) | 0.05 | 0.09 | 2.96 | 1.38 | 4.89 | |
| Total Debt/Equity (X) | 2.18 | 2.19 | 2.37 | 2.82 | 2.86 | |
| Asset Turnover Ratio (%) | 34.23 | 37.79 | 46.98 | 45.83 | 60.87 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.73 | 1.87 | 2.74 | 3.98 | 5.83 | |
| Quick Ratio (X) | 1.03 | 0.85 | 1.58 | 2.60 | 4.54 | |
| Inventory Turnover Ratio (X) | 2.38 | 2.03 | 1.91 | 1.86 | 3.82 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 513.37 | 471.82 | 940.11 | 357.25 | 935.54 | |
| EV/Net Operating Revenue (X) | 2.60 | 2.36 | 3.97 | 1.56 | 3.29 | |
| EV/EBITDA (X) | 20.34 | 17.31 | 24.05 | 12.59 | 18.82 | |
| MarketCap/Net Operating Revenue (X) | 0.91 | 0.76 | 2.82 | 0.80 | 2.87 | |
| Retention Ratios (%) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Price/BV (X) | 1.11 | 1.05 | 5.21 | 1.62 | 7.71 | |
| Price/Net Operating Revenue | 0.91 | 0.76 | 2.82 | 0.80 | 2.87 | |
| Earnings Yield | 0.00 | 0.00 | 0.02 | 0.04 | 0.03 |
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
09.09.2025
Marksans Pharma Standalone June 2025 Net Sales at Rs 319.73 crore, up 25.62% Y-o-Y
20.05.2025
Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y